Study Examines Patient Perceptions of Marijuana as Glaucoma Treatment
Research shows patients with glaucoma are likely to encounter conflicting opinions on marijuana’s role in glaucoma therapy, especially from dispensaries.
Research shows patients with glaucoma are likely to encounter conflicting opinions on marijuana’s role in glaucoma therapy, especially from dispensaries.
A growing body of research shows SLT for first-line glaucoma therapy works as well as drops — so why aren’t clinician’s embracing it?
The new approvals are the latest in Johnson & Johnson’s IOLs; the Company claims the new TECNIS Eyhance IOL can slightly extend the depth of focus and deliver better image contrast.
The NDA submission is supported by data from the phase 3 MIST-1 and MIST-2 studies.
As both the vaccine and Tepezza are being manufactured at Catalent, the government has prioritized the manufacturing of the vaccine thereby resulting in cancellation of previously contracted Tepezza orders.
The Food and Drug Administration approved Cystadrops in August 2020.
Levodopa is safe and well-tolerated, improves visual outcomes, and delays anti-VEGF treatment.
Cystinosis is a rare, multisystem genetic disorder caused by an accumulation of cystine crystals throughout the body, including the eyes.
According to the Agency, 29 reports of TASS were identified following a search of the FDA Adverse Event Reporting System database through December 19, 2019.
The FDA has approved Upneeq™ (oxymetazoline hydrochloride ophthalmic solution; Osmotica) for the treatment of acquired blepharoptosis in adults.